Samsung Biologics nears full takeover of Polypeptide in 2.4 trillion-won deal
Samsung Biologics(207940) secured 97.98% equity in the tender offer for the global peptide contract development and manufacturing organizations (CDMO) corporations PolyPeptide…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 2 02:47 ETSource: Chosunbiz
From the source
Read at biz.chosun.comSamsung Biologics nears full takeover of Polypeptide in 2.4 trillion-won deal
Samsung Biologics(207940) secured 97.98% equity in the tender offer for the global peptide contract development and manufacturing organizations (CDMO) corporations PolyPeptide Group. Meeting the requirements to forcibly purchase the remaining equity, the acquisition has entered its final stage. After approvals from overseas regulators, the plan is to close the transaction as early as the end of th
